Updated Jul 16, 2026
Porter James Richard has filed 4 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $36.93M.
James Richard Porter is the President and CEO of Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Under his leadership, the company is advancing innovative treatments aimed at overcoming existing therapy limitations.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | NUVL | Nuvalent, Inc. | D — Derivative transaction | 40.0K | — | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | A — Grant or award | 40.0K | $0.00 | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | D — Derivative transaction | 121.3K | — | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | J — Other acquisition / disposition | 203.5K | $124.00 | $25.24M |
| 2026-07-08 | NUVL | Nuvalent, Inc. | S — Open-market sale | 30.0K | $123.72 | $3.71M |
| 2026-07-08 | NUVL | Nuvalent, Inc. | M — Option exercise | 30.0K | $18.93 | $568K |
| 2026-06-10 | NUVL | Nuvalent, Inc. | S — Open-market sale | 3.0K | $89.63 | $272K |
| 2026-06-10 | NUVL | Nuvalent, Inc. | S — Open-market sale | 14.5K | $88.79 | $1.28M |
| 2026-06-10 | NUVL | Nuvalent, Inc. | S — Open-market sale | 12.5K | $87.97 | $1.10M |
| 2026-06-10 | NUVL | Nuvalent, Inc. | M — Option exercise | 30.0K | $18.93 | $568K |
| 2026-05-06 | NUVL | Nuvalent, Inc. | S — Open-market sale | 2.1K | $102.88 | $217K |
| 2026-05-06 | NUVL | Nuvalent, Inc. | S — Open-market sale | 17.4K | $102.10 | $1.77M |
| 2026-05-06 | NUVL | Nuvalent, Inc. | S — Open-market sale | 7.4K | $101.48 | $754K |
| 2026-05-06 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.4K | $99.77 | $140K |
| 2026-05-06 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.7K | $98.54 | $167K |
| 2026-05-06 | NUVL | Nuvalent, Inc. | M — Option exercise | 30.0K | $18.93 | $568K |
| 2026-04-08 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 100 | $105.60 | $11K |
| 2026-04-08 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 6.1K | $104.78 | $641K |
| 2026-04-08 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 12.4K | $103.78 | $1.29M |
| 2026-04-08 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 11.4K | $103.21 | $1.17M |
James Richard Porter is the President and CEO of Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Under his leadership, the company is advancing innovative treatments aimed at overcoming existing therapy limitations.…
4 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 49 open-market sales ($36.93M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Porter James Richard profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.